Summary Wilson Therapeutics AB (Wilson Therapeutics), a subsidiary of Alexion Pharma Nordics AB, is a biopharmaceutical company that develops novel therapies for patients with rare copper-mediated disorders.The company’s lead product includes WTX101 is a copper-protein-binding agent, which is used for the treatment for wilson disease.
Its product provides an alternative copper-protein transport mechanism, copper-protein complexes, de-toxify free copper and biliary excretion of copper.Wilson Therapeutics’ lead product is also used for the treatment of other medical conditions including amyotrophic lateral sclerosis.
The company conducts clinical trials for developing the treatment of wilson disease. Wilson Therapeutics is headquartered in Stockholm, Sweden.
Wilson Therapeutics AB (WTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
184 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Algae Fats Market to Reach $1.2 Billion by 2027
- Amid the COVID-19 crisis, the global market for Algae Fats estimated at US$875.5 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2027, growing at aCAGR of 4.9% over the period 2020-2027. Foods & Supplements, one...
Sarcopenia (Musculoskeletal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Drugs in Development, 2021, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape. Sarcopenia is an aging-associated...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report
The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021–2026.
The global IV and oral iron drugs market is expected to grow due to the prevalence...
Amyloidosis (Metabolic Disorder) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Drugs in Development, 2021, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape. Abnormal accumulation of amyloid...
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021 Summary Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 17 molecules. Out...
The Veterinary Pain management market was valued at USD 1,197 million in 2020, and it is expected to reach USD 1,910 million in 2026, registering a CAGR of nearly 6.30% during the forecast period. The global outbreak of COVID-19 has impacted all industries including veterinary pain medicine. Pet parents are advised to keep a safe distance...
187 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Viscosupplementation Market to Reach $6.8 Billion by 2027
- Amid the COVID-19 crisis, the global market for Viscosupplementation estimated at US$4 Billion in the year 2020, is projected to reach a revised size of US$6.8 Billion by 2027, growing at a CAGR of 7.7% over the analysis period 2020-2027....
216 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Inflammatory Bowel Disease (IBD) Therapeutics Market to Reach $7.2 Billion by 2027
- Amid the COVID-19 crisis, the global market for Inflammatory Bowel Disease (IBD) Therapeutics estimated at US$6.8 Billion in the year 2020, is projected to reach a revised size of US$7.2 Billion by 2027, growing...
Pharmaceutical
Therapy
Autoimmune Disease
World
China
United States
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.